Impact of the HeartMate 3 continuous-flow left ventricular assist device in patients with small body size.

Kohei Tonai Satsuki Fukushima Naoki TadokoroSatoshi KainumaNaonori KawamotoTakashi KakutaAyumi Koga-IkutaTakuya WatanabeOsamu SeguchiYasumasa TsukamotoNorihide FukushimaTomoyuki Fujita

Published in: Interactive cardiovascular and thoracic surgery (2022)

The HM 3 was safely implanted in patients with a small BSA, and postoperative outcomes were acceptable regardless of BSA. However, further research is needed to confirm the indications for HM 3 implantation in even smaller patients.

Keyphrases

left ventricular assist device
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
patients undergoing
type diabetes